JNJ-39393406

In today's world, JNJ-39393406 has become a topic of great relevance and interest to a wide spectrum of people. Both professionally and personally, JNJ-39393406 has generated debates and discussions about its impact and influence on society. From its origin to its current evolution, JNJ-39393406 has been the subject of studies and research that have tried to shed light on its implications and consequences. In this article, we will explore some fundamental aspects of JNJ-39393406 and analyze its role in different contexts. From its connection with technology, through its relationship with culture and politics, to its importance in everyday life, JNJ-39393406 is a topic that continues to generate interest and reflection today.

JNJ-39393406
Clinical data
Routes of
administration		By mouth[1]
Drug classAntinicotinic
Identifiers
  • 3--5-pyridin-4-yl-1,2,4-triazol-1-yl]-N,N-dimethylpropanamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H18F2N6O3
Molar mass416.389 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)CCN1C(=NC(=N1)NC2=CC3=C(C=C2)OC(O3)(F)F)C4=CC=NC=C4
  • InChI=1S/C19H18F2N6O3/c1-26(2)16(28)7-10-27-17(12-5-8-22-9-6-12)24-18(25-27)23-13-3-4-14-15(11-13)30-19(20,21)29-14/h3-6,8-9,11H,7,10H2,1-2H3,(H,23,25)
  • Key:IURMHZBQEYNQOH-UHFFFAOYSA-N

JNJ-39393406 is an experimental medication which is under development by Janssen Pharmaceutica, a division of Johnson & Johnson, for the treatment of depressive disorders and smoking withdrawal.[1] It acts as a selective positive allosteric modulator of the α7 nicotinic acetylcholine receptor (nAChR).[1] It does not act on the α4β2 or α3β4 nAChRs or the serotonin 5-HT3 receptor, and does not interact with a panel of 62 other receptors and enzymes.[2] The drug has been found to lower the agonist and nicotine threshold for activation of the α7 nAChR by 10- to 20-fold and to increase the maximum agonist response of the α7 nAChR by 17- to 20-fold.[2]

As of February 2018, JNJ-39393406 is in phase II clinical trials for both depressive disorders and smoking withdrawal.[1] It was also under investigation for the treatment of schizophrenia and Alzheimer's disease, but development for these indications was discontinued.[1]

See also

References

  1. ^ a b c d e "JNJ-39393406". Adis Insight.
  2. ^ a b Winterer G, Gallinat J, Brinkmeyer J, Musso F, Kornhuber J, Thuerauf N, Rujescu D, Favis R, Sun Y, Franc MA, Ouwerkerk-Mahadevan S, Janssens L, Timmers M, Streffer JR (2013). "Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study". Neuropharmacology. 64: 197–204. doi:10.1016/j.neuropharm.2012.06.040. PMID 22766391. S2CID 29118435.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.